A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation

Hepatology

Volumn 64, Issue 2, 2016, Pages 632-643

  Todo, Satoru ^a   Yamashita, Kenichiro ^a   Goto, Ryoichi ^a   Zaitsu, Masaaki ^a   Nagatsu, Akihisa ^a   Oura, Tetsu ^a   Watanabe, Masaaki ^a   Aoyagi, Takeshi ^a   Suzuki, Tomomi ^a   Shimamura, Tsuyoshi ^b   Kamiyama, Toshiya ^a   Sato, Norihiro ^b   Sugita, Junichi ^b   Hatanaka, Kanako ^a   Bashuda, Hisashi ^c   Habu, Sonoko ^c   Demetris, Anthony J ^d   Okumura, Ko ^c  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADOPTIVE TRANSFER; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE LIVER DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CLINICAL ARTICLE; COCULTURE; DRUG WITHDRAWAL; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL MONITORING; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LEUKOCYTE COUNT; LIVER FUNCTION TEST; LIVER GRAFT REJECTION; LIVER HISTOLOGY; LIVER TRANSPLANTATION; LIVING DONOR; MALE; PHENOTYPE; PILOT STUDY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TREATMENT WITHDRAWAL;

EID: 84979047235     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28459     Document Type: Article

References (46)

1. Starzl T, Demetris A, Trucco M, Murase N, Ricordi C, Ildstad S, et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology 1993;17:1127-1152.
2. Mazariegos G, Reyes J, Marino I, Demetris A, Flynn B, Irish W, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997;63:243-249.
3. Tryphonopoulos P, Tzakis A, Weppler D, Garcia-Morales R, Kato T, Madariaga J, et al. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am J Transplant 2005;5:608-613.
4. Starzl T, Murase N, Abu-Elmagd K, Gray E, Shapiro R, Eghtesad B, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003;361:1502-1510.
5. Yoshizawa A, Takada Y, Fujimoto Y, Koshiba T, Haga H, Nabeshima S, et al. Liver transplantation from an identical twin without immunosuppression, with early recurrence of hepatitis C. Am J Transplant 2006;6:2812-2816.
6. Alexander SI, Smith N, Hu M, Verran D, Shun A, Dorney S, et al. Chimerism and tolerance in a recipient of a deceased-donor liver transplant. N Engl J Med 2008;358:369-374.
7. Orlando G, Soker S, Wood KJ . Operational tolerance after liver transplantation. J Hepatol 2009;50:1247-1257.
8. Katharyn Wood KJ, Bushell A, Hester J . Regulatory immune cells in transplantation. Nat Rev Immunol 2012;25:417-430.
9. Gershon RK, Kondo K . Infectious immunological tolerance. Immunology 1971;21:903-914.
10. Okumura K, Tomita T . Regulation of homocytotropic antibody formation in the rat: VI. Inhibitory effect of thymocytes on the homocytotropic antibody response. J Immunol 1971;107;1682-1689.
11. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M . Immunologic self-tolerance maintained by activated T cells expressing IL-2 recepter alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-1164.
12. Van Gool SW, Vermeiren J, Rafiq K, Lorr K, de Boer M, Ceuppens JL . Blocking CD40-CD154 and CD80/CD86-CD28 interactions during primary allogeneic stimulation results in T cell anergy and high IL-10 production. Eur J Immunol 1999;29:2367-2375.
13. Davies JK, Gribben JG, Brennan LL, Lee DY, Nadler LM, Guinan EC . Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies. Blood 2008;112:2232-2241.
14. Levitsky J, Miller J, Leventhal J, Huang X, Flaa C, Eang E, et al. The human ‘Treg MLR’: immune monitoring for Foxp3+ T regulatory cell generation. Transplantation 2009;88:1303-1311.
15. Fujiki M, Esquivel CO, Martinez OM, Strober S, Uemoto S, Krams SM . Induced tolerance to rat liver allografts involves the apoptosis of intragraft T cells and the generation of CD4(+)CD25(+)FoxP3(+) T regulatory cells. Liver Transpl 2010;16:147-154.
16. Pons JA, Revilla-Nuin B, Baroja-Mazo A, Ramírez P, Martínez-Alarcón L, Sánchez-Bueno F, et al. FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal. Transplantation 2008;86:1370-1378.
17. Li Y, Zhao X, Cheng D, Haga H, Tsuruyama T, Wood K, et al. The presence of Foxp3 expressing T cells within grafts of tolerant human liver transplant recipients. Transplantation 2008;86:1837-1843.
18. Bashuda H, Kimikawa M, Seino K, Kato Y, Ono F, Shimizu A, et al. Renal allograft rejection is prevented by adoptive transfer of anergic T cells in nonhuman primates. J Clin Invest 2005;115:1896-1902.
19. Koyama I, Bashuda H, Seino K, Yagi J, Fujii H, Nakajima I, et al. Induction of donor htporesponsiveness by adoptive transfer of ex vivo expanded anergic cells. Am J Transplant 2011;11(Suppl. S2):77.
20. Taniguchi M, Shimamura T, Todo S, Furukawa H . Small-for-size syndrome in living-donor liver transplantation using a left lobe graft. Surg Today 2015;45:663-671.
21. Ashton-Chess J, Giral M, Brouard S, Soulillou JP . Spontaneous operational tolerance after immunosuppressive drug withdrawal in clinical renal allotransplantation. Transplantation 2007;84:1215-1219.
22. Leventhal JR, Elliott MJ, Yolcu ES, Bozulic LD, Tollerud DJ, Mathew JM, et al. Immune reconstitution/immunocompetence in recipients of kidney plus hematopoietic stem/facilitating cell transplants. Transplantation 2015;99:288-298.
23. Kawai T, Sachs DH, Sykes M, Cosimi AB Immune Tolerance Network. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2013 9;368:1850-1852.
24. Brunstein C, Miller J, Cao Q, McKenna D, Hippen K, Curtsinger J, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011;117:1061-1070.
25. Guinanm E, Boussiotis V, Neuberg D, Brennan L, Hirano N, Nadler M, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999;340:1704-1714.
26. Pahwa R, Jaggaiahgari S, Pahwa S, Inverardi L, Tzakis A, Ricordi C . Isolation and expansion of human natural T regulatory cells for cellular therapy. J Immunol Methods 2010;363:67-79.
27. Schwartz RH . A cell culture model for T lymphocyte clonal anergy. Science 1990;248:1349-1356.
28. Davies JK, Barbon C, Voskertchian A, Nadler L, Guinan EC . Ex vivo alloanergization with Belatacept: a strategy to selectively modulate alloresponses after transplantation. Cell Transplant 2012;21:2047-2061.
29. Tang Q, Bluestone JA . Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med 2013;3:1-15.
30. Marek-Trzonkowska N, Myśliwec M, Siebert J, Trzonkowski P . Clinical application of regulatory T cells in type 1 diabetes. Pediatr Diabetes 2013;14:322-332.
31. Nagatsu A, Yamashita K, Zaitsyu S, Goto R, Oura T, Watanabe M, et al. Ex-vivo generation of immunosuppressive human cells by co-culture of recipient and irradiated donor PBMCs under CD80/CD86 costimulation blockade. Am J Transplant 2013;ATC abstract (Number A 753).
32. Luznik L, O'Donnell PV, Fuchs EJ . Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol 2012;39:683-693.
33. Benıtez C, Londono MC, Miquel R, Manzia T, Abrraldes J, Lozano JJ, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology 2013;58:1824-1835.
34. Takatsuki M, Uemoto S, Inomata Y, Egawa H, Kiuchi T, Fujita S, et al. Weaning of immunosuppression in living liver transplant recipients. Transplantation 2001;72:449-454.
35. Feng S, Ekong UD, Lobritto SJ, Demetris A, Roberts J, Rosenthal P, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012;307:283-293.
36. Marcos A, Eghtesad B, Fung JJ, Fontes P, Patel K, Devera M, et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004;78:966-971.
37. Egawa H, Ueda Y, Ichida T, et al. Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation in Japanese registry. Am J Transplant 2011;11:518-527.
38. Manzia TM, Angelico R, Baiocchi L, Toti L, Ciano P, Palmieri G, et al. The Tor Vergata weaning of immunosuppression protocols in stable hepatitis C virus liver transplant patients: the 10-year follow-up. Transpl Int 2013;26:259-266.
39. Lan RY, Cheng C, Lian ZX, Tsuneyama K, Yang G, Moritoki Y, et al. Liver-targeted and peripheral blood alterations of regulatory T Cells in primary biliary cirrhosis. Hepatology 2006;43:729-737.
40. Sebode M, Peiseler M, Franke1 B, Schwinge T, Wortmann F, Quaas A, et al. Reduced FOXP3+ regulatory T cells in patients with primary sclerosing cholangitis are associated with IL2RA gene polymorphisms. J Hepatol 2014;60:1010-1016.
41. Orlando G, Hematti P, Stratta RJ, Burke GW 3rd, Di Cocco P, Pisani F, et al. Clinical operational tolerance after renal transplantation: current status and future challenges. Ann Surg 2010;252:915-928.
42. Morris H, Dewolf S, Robins H, Sprangers B, LoCascio, Shonts BA, et al. Tracking donor-reactive T cells: evidence for clonal deletion in tolerant kidney transplant patients. Sci Transl Med 2015;7:272ra10.
43. Starzl TE, Murase N, Eghtesad B, Abu-Elmagd K, Demetris AJ, Fung J . In Busuttil RW, Kintmalm GB, eds. Transplantation of the Liver, 3rd ed. Philadelphia, PAS: Elsevier Saunders; 2015:1227-1244.
44. Leventhal J, Abecassis M, Miller J, Gallon L, Tollerud D, Elliott MJ, et al. Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome. Transplantation 2013;95:169-176.
45. Zhang N, Schröppel B, Lal G, Jakubzick C, Maso X, Chen D, et al. Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity 2009;30:458-469.
46. Kendal AR, Waldmann H . Infectious tolerance: therapeutic potential. Curr Opin Immunol 2010;22:560-565.